OR WAIT null SECS
April 14, 2016.
The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, according to GBI Research.
GBI's Fiona Chisholm commented: “Some 1,848 pipeline products are specifically in development for the treatment of viral infections, accounting for a sizeable proportion of the infectious diseases pipeline. Among these products, HIV has the most at an active stage of development, with 419, followed by influenza, Hepatitis C and Hepatitis B, with 333, 222 and 150 pipeline products, respectively.
“Such strong activity is indicative of a high degree of commercial interest in viral infections in general, and in these key indications in particular, which reflects the commercial success of currently marketed products such as Truvada, Atripla and Harvoni. However, it should be noted that many products in the viral infections pipeline are being developed for multiple indications, including infectious diseases attributable to non-viral micro-organisms.”
states that generic penetration in this market is also projected to increase considerably over the forecast period, especially in the seven major markets of the US, France, Germany, Italy, the UK, Spain, and Japan. However, Chisholm added, "the strength of innovation will continue to drive the global viral infections space, as demonstrated by the strong growth.”